1
|
Song Y, Kirsch G, Jarjour W. The Utility of Ultrasound in Evaluating Joint Pain in Systemic Lupus Erythematosus: Looking beyond Fibromyalgia. J Pers Med 2023; 13:jpm13050763. [PMID: 37240932 DOI: 10.3390/jpm13050763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 04/26/2023] [Accepted: 04/27/2023] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND Systemic lupus erythematosus (SLE) is a complex autoimmune condition with varied clinical presentations, and musculoskeletal pain is one of the most commonly associated symptoms. However, fibromyalgia (FM) is a prevalent co-existing condition in SLE patients that can also cause widespread pain, and in patients with both conditions, it is often difficult to distinguish the underlying cause of musculoskeletal pain and provide optimal therapy. METHODS A retrospective cohort study was conducted including all adult SLE patients who received musculoskeletal ultrasound (US) examinations for joint pain at the Ohio State University Wexner Medical Center between 1 July 2012, and 30 June 2022. Binary and multiple logistic regression analyses were performed to determine predictors of US-detected inflammatory arthritis as well as improved musculoskeletal pain. RESULTS A total of 31 of 72 SLE patients (43.1%) had a co-existing diagnosis of FM. In binary logistic regression, a co-existing diagnosis of FM was not significantly associated with US-detected inflammatory arthritis. In multiple logistic regression analysis, clinically detected synovitis was significantly associated with US-detected inflammatory arthritis (aOR, 142.35, p < 0.01), and there was also a weak association with erythrocyte sedimentation rate (ESR) (aOR 1.04, p = 0.05). In separate multiple logistic regression analysis, US-guided intra-articular steroid injection was the only predictor of improved joint pain at follow-up visit (aOR 18.43, p < 0.001). CONCLUSIONS Musculoskeletal US can be an effective modality to detect inflammatory arthritis as well as to guide targeted intra-articular steroid injection to alleviate joint pain in SLE patients with or without FM.
Collapse
Affiliation(s)
- Yeohan Song
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
- Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Gabriel Kirsch
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Wael Jarjour
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
- Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| |
Collapse
|
2
|
Shankar D, Merchand-Reyes G, Buteyn NJ, Santhanam R, Fang H, Kumar K, Mo X, Ganesan LP, Jarjour W, Butchar JP, Tridandapani S. Inhibition of BET Proteins Regulates Fcγ Receptor Function and Reduces Inflammation in Rheumatoid Arthritis. Int J Mol Sci 2023; 24:7623. [PMID: 37108786 PMCID: PMC10143512 DOI: 10.3390/ijms24087623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 03/30/2023] [Accepted: 04/19/2023] [Indexed: 04/29/2023] Open
Abstract
Overactivation of immune responses is a hallmark of autoimmune disease pathogenesis. This includes the heightened production of inflammatory cytokines such as Tumor Necrosis Factor α (TNFα), and the secretion of autoantibodies such as isotypes of rheumatoid factor (RF) and anticitrullinated protein antibody (ACPA). Fcγ receptors (FcγR) expressed on the surface of myeloid cells bind Immunoglobulin G (IgG) immune complexes. Recognition of autoantigen-antibody complexes by FcγR induces an inflammatory phenotype that results in tissue damage and further escalation of the inflammatory response. Bromodomain and extra-terminal protein (BET) inhibition is associated with reduced immune responses, making the BET family a potential therapeutic target for autoimmune diseases such as rheumatoid arthritis (RA). In this paper, we examined the BET inhibitor PLX51107 and its effect on regulating FcγR expression and function in RA. PLX51107 significantly downregulated expression of FcγRIIa, FcγRIIb, FcγRIIIa, and the common γ-chain, FcϵR1-γ, in both healthy donor and RA patient monocytes. Consistent with this, PLX51107 treatment attenuated signaling events downstream of FcγR activation. This was accompanied by a significant decrease in phagocytosis and TNFα production. Finally, in a collagen-induced arthritis model, PLX51107-treatment reduced FcγR expression in vivo accompanied by a significant reduction in footpad swelling. These results suggest that BET inhibition is a novel therapeutic approach that requires further exploration as a treatment for patients with RA.
Collapse
Affiliation(s)
- Divya Shankar
- College of Medicine, The Ohio State University, Columbus, OH 43210, USA
| | | | | | - Ramasamy Santhanam
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Huiqing Fang
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Krishan Kumar
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Xiaokui Mo
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA
| | - Latha P. Ganesan
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Wael Jarjour
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Jonathan P. Butchar
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
| | | |
Collapse
|
3
|
Parikh SV, Malvar A, Song H, Shapiro J, Mejia-Vilet JM, Ayoub I, Almaani S, Madhavan S, Alberton V, Besso C, Lococo B, Satoskar A, Zhang J, Yu L, Fadda P, Eadon M, Birmingham D, Ganesan LP, Jarjour W, Rovin BH. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int 2022; 102:845-865. [PMID: 35788359 PMCID: PMC9613357 DOI: 10.1016/j.kint.2022.05.033] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 05/11/2022] [Accepted: 05/16/2022] [Indexed: 11/29/2022]
Abstract
The immune pathways that define treatment response and non-response in lupus nephritis (LN) are unknown. To characterize these intra-kidney pathways, transcriptomic analysis was done on protocol kidney biopsies obtained at flare (initial biopsy (Bx1)) and after treatment (second biopsy (Bx2)) in 58 patients with LN. Glomeruli and tubulointerstitial compartments were isolated using laser microdissection. RNA was extracted and analyzed by nanostring technology with transcript expression from clinically complete responders, partial responders and non-responders compared at Bx1 and Bx2 and to the healthy controls. Top transcripts that differentiate clinically complete responders from non-responders were validated at the protein level by confocal microscopy and urine ELISA. At Bx1, cluster analysis determined that glomerular integrin, neutrophil, chemokines/cytokines and tubulointerstitial chemokines, T cell and leukocyte adhesion genes were able to differentiate non-responders from clinically complete responders. At Bx2, glomerular monocyte, extracellular matrix, and interferon, and tubulointerstitial interferon, complement, and T cell transcripts differentiated non-responders from clinically complete responders. Protein analysis identified several protein products of overexpressed glomerular and tubulointerstitial transcripts at LN flare, recapitulating top transcript findings. Urine complement component 5a and fibronectin-1 protein levels reflected complement and fibronectin expression at flare and after treatment. Thus, transcript analysis of serial LN kidney biopsies demonstrated how gene expression in the kidney changes with clinically successful and unsuccessful therapy. Hence, these insights into the molecular landscape of response and non-response may help align LN management with the pathogenesis of kidney injury.
Collapse
Affiliation(s)
- Samir V Parikh
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
| | - Ana Malvar
- Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina
| | - Huijuan Song
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - John Shapiro
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Juan Manuel Mejia-Vilet
- Department of Nephrology and Mineral Metabolism, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico; Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico
| | - Isabelle Ayoub
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Salem Almaani
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Sethu Madhavan
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Valeria Alberton
- Department of Pathology, Hospital Fernandez, Buenos Aires, Argentina
| | - Celeste Besso
- Department of Pathology, Hospital Fernandez, Buenos Aires, Argentina
| | - Bruno Lococo
- Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina
| | - Anjali Satoskar
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Jianying Zhang
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Lianbo Yu
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Paolo Fadda
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Michael Eadon
- Department of Medicine, Indiana University, Indianapolis, Indiana, USA
| | - Dan Birmingham
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Latha P Ganesan
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Wael Jarjour
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Brad H Rovin
- Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| |
Collapse
|
4
|
Herling M, Jarjour W, Mishra A, Brammer JE. Editorial: Pathogenesis, treatment, and future directions for rare T-cell leukemias. Front Oncol 2022; 12:991527. [PMID: 36158669 PMCID: PMC9490408 DOI: 10.3389/fonc.2022.991527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 08/23/2022] [Indexed: 11/21/2022] Open
Affiliation(s)
- Marco Herling
- Department of Hematology, Cellular Therapy, and Hemostasis University of Leipzig, Leipzig, Germany
- Department of Internal Medicine, Center for Integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Duesseldorf, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne (UoC), Cologne, Germany
| | - Wael Jarjour
- Division of Rheumatology, The Ohio State University, Columbus, OH, United States
| | - Anjali Mishra
- Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Jonathan E. Brammer
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- *Correspondence: Jonathan E. Brammer,
| |
Collapse
|
5
|
Couette N, Jarjour W, Brammer JE, Simon Meara A. Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease. Front Oncol 2022; 12:854499. [PMID: 35747794 PMCID: PMC9209697 DOI: 10.3389/fonc.2022.854499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 04/26/2022] [Indexed: 11/30/2022] Open
Abstract
A complex relationship exists between rheumatic diseases and cancer. This delicate balance between chronic inflammation and malignant cell transformation in hematologic neoplasms has been observed, but is not well defined. Large Granular Lymphocyte (LGL) leukemia is at the intersection of a clonal lymphoproliferative disease, chronic inflammation, and autoimmunity. The association between rheumatoid arthritis (RA) and the spectrum of Felty’s Syndrome is well-known. Other rheumatic disorders have been reported including systemic lupus erythematosus (SLE), Sjogren’s Syndrome (SS), vasculitis, Behcet’s Disease (BD) and systemic sclerosis. The association between T-LGLL and rheumatic disease pathogenesis has been hypothesized, but has not yet been fully understood. Components of a shared pathogenesis includes chronic antigen stimulation, JAK-STAT pathway activation and overlap of various cytokines. We will summarize current knowledge on the molecular understanding between T-LGLL and rheumatic disease. There are many potential areas of research to help meet this need and lead to development of targeted therapeutic options.
Collapse
|
6
|
Braunstein Z, McLaughlin E, Ruiz M, Wei L, Bumma N, Benson D, Devarakonda S, Chaudhry M, Khan A, Cottini F, Hanel W, Baiocchi R, Chung C, Addison D, Couette N, Meara A, Jarjour W, Porcu P, Mishra A, Reneau JC, Rosko AE, Brammer JE. Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. Front Oncol 2022; 12:858426. [PMID: 35574379 PMCID: PMC9106372 DOI: 10.3389/fonc.2022.858426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 03/07/2022] [Indexed: 11/13/2022] Open
Abstract
T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs.
Collapse
Affiliation(s)
- Zachary Braunstein
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Eric McLaughlin
- Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, United States
| | - Miguel Ruiz
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Lai Wei
- Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, United States
| | - Naresh Bumma
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Don Benson
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Srinivas Devarakonda
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Maria Chaudhry
- Division of Hematology, George Washington Cancer Center, George Washington University, Washington, DC, United States
| | - Abdullah Khan
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Francesca Cottini
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Walter Hanel
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Robert Baiocchi
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Catherine Chung
- Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Daniel Addison
- Cardio-Oncology Program, Division of Cardiology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Nina Couette
- Division of Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Alexa Meara
- Division of Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Wael Jarjour
- Division of Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Pierluigi Porcu
- Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Anjali Mishra
- Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - John C. Reneau
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Ashley E. Rosko
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| | - Jonathan E. Brammer
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
| |
Collapse
|
7
|
Hanaoka BY, Zhao J, Heitman K, Khan F, Jarjour W, Volek J, Brock G, Gower BA. Interaction effect of systemic inflammation and modifiable rheumatoid cachexia risk factors on resting energy expenditure in patients with rheumatoid arthritis. JCSM Clin Rep 2022; 7:12-23. [PMID: 38288252 PMCID: PMC10824535 DOI: 10.1002/crt2.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 11/13/2021] [Indexed: 12/14/2022] Open
Abstract
Background In rheumatoid cachexia (RC), high resting energy expenditure (REE) is associated with loss of muscle mass driven by proinflammatory cytokines. The objectives of this study were to investigate parameters associated with RC, and the interaction between systemic inflammation and modifiable risk factors for RC on REE. Methods Thirty-five rheumatoid arthritis (RA) and nineteen non-RA controls comparable in age, sex, race and BMI underwent measures of REE by indirect calorimetry. Clinical, dietary, body composition and physical function data were collected. Homeostasis model assessment for insulin resistance (HOMA-IR) and serum interleukin-6 (IL-6) were used as parameters of IR and systemic inflammation, respectively. Regression models tested association between REE and dependent variables, including pre-specified interaction tests involving HOMA-IR and IL-6 and dietary intake of protein per weight (PPW) and IL-6. Results RA subjects were mostly women (94%) and had a median age of 54 years (50.5, 70) and BMI of 30.5 kg/m2 (26.1, 36.9). We observed a significant interaction effect between PPW and serum IL-6 on REE among RA subjects in the multiple regression model among RA. The upper tertile of PPW demonstrated a significant negative correlation between REE and IL-6 (β=-19.97, 95% CI [-35.41, -4.54], p=0.01). The lower tertile of PPW demonstrated a significant positive correlation between REE and IL-6 (β=42.24, 95% CI [4.25, 80.23], p=0.03). Conclusions While IR can lead to muscle catabolism, IR was not significantly associated with REE in RA individuals. Higher dietary protein intake could attenuate the effect of systemic inflammation on REE in RA patients.
Collapse
Affiliation(s)
- Beatriz Y Hanaoka
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Jing Zhao
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Kristen Heitman
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Fahad Khan
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Wael Jarjour
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Jeff Volek
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Guy Brock
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| | - Barbara A Gower
- Division of Rheumatology-Immunology, McCampbell Hall, 1581 Dodd Drive, Room 505, Columbus, OH, 43210
| |
Collapse
|
8
|
Abstract
SARS-CoV-2 has been described to cause "COVID [coronavirus disease] toes," a chilblains-like syndrome.1,2,3 A 33-year-old White woman was evaluated in the hospital for painful new-onset blue and purple nodules on the tips of 3 fingers and 2 toes, 7 days after receiving the Moderna SARS-CoV-2 vaccine (Figure 1).
Collapse
Affiliation(s)
- Alexa Simon Meara
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Address correspondence to Dr. A.S. Meara, Assistant Professor, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, 480 Medical Center Drive, Davis Building, Suite 2058, Columbus, OH 43210, USA. . The authors declare no conflicts of interest. The patient's written informed consent to publish the material was obtained. No institutional review board approval was required according to the authors' institution
| | - Molly Silkoski
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Address correspondence to Dr. A.S. Meara, Assistant Professor, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, 480 Medical Center Drive, Davis Building, Suite 2058, Columbus, OH 43210, USA. . The authors declare no conflicts of interest. The patient's written informed consent to publish the material was obtained. No institutional review board approval was required according to the authors' institution
| | - Kai Quin
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Address correspondence to Dr. A.S. Meara, Assistant Professor, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, 480 Medical Center Drive, Davis Building, Suite 2058, Columbus, OH 43210, USA. . The authors declare no conflicts of interest. The patient's written informed consent to publish the material was obtained. No institutional review board approval was required according to the authors' institution
| | - Wael Jarjour
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Address correspondence to Dr. A.S. Meara, Assistant Professor, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, 480 Medical Center Drive, Davis Building, Suite 2058, Columbus, OH 43210, USA. . The authors declare no conflicts of interest. The patient's written informed consent to publish the material was obtained. No institutional review board approval was required according to the authors' institution
| |
Collapse
|
9
|
Schlesinger N, Lipsky PE, Jablonski K, Jarjour W, Brunetti L, Young NA. Components of tart cherry juice inhibit NFκB activation and inflammation in acute gout. Clin Exp Rheumatol 2021; 40:1293-1298. [DOI: 10.55563/clinexprheumatol/xnb7hp] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 07/09/2021] [Indexed: 11/13/2022]
Affiliation(s)
- Naomi Schlesinger
- Gout Center and Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
| | | | - Kyle Jablonski
- Division of Immunology and Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Wael Jarjour
- Division of Immunology and Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | | | - Nicholas A. Young
- Division of Immunology and Rheumatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|
10
|
Toribio RE, Young N, Schlesinger LS, Cope FO, Ralph DA, Jarjour W, Rosol TJ. Cy3-tilmanocept labeling of macrophages in joints of mice with antibody-induced arthritis and synovium of human patients with rheumatoid arthritis. J Orthop Res 2021; 39:821-830. [PMID: 33107629 DOI: 10.1002/jor.24900] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 10/10/2020] [Accepted: 10/21/2020] [Indexed: 02/04/2023]
Abstract
γ-Tilmanocept (99m Tc-tilmanocept) is a receptor-directed, radiolabeled tracer that is FDA-approved for guiding sentinel lymph node biopsy. Tilmanocept binds the C-type lectin mannose receptor (MR, CD206) on macrophages. In this study, nonradioactive, fluorescently-labeled Cy3-tilmanocept was used to detect CD206+ mononuclear cells in the cartilage of mice with antibody-induced arthritis and in the synovial fluid and tissue of human subjects with rheumatoid arthritis (RA) for comparison with osteoarthritis (OA), and healthy volunteer (HV) controls. Murine arthritis was induced by injection of monoclonal anti-cartilage antibody followed by injection of Escherichia coli lipopolysaccharide. Post-arthritis development (7-11 days), the mice were injected intravenously with Cy3-tilmanocept followed by in vivo and ex vivo epifluorescence imaging. Two-photon imaging, immunofluorescence, and immunohistochemistry were used to identify articular and synovial macrophages (CD206, F4/80, and Cy3-tilmanocept binding) in murine tissues. Cy3-tilmanocept epifluorescence was present in arthritic knees and elbows of murine tissues; no radiographic changes were noted in the skeletons. However, inflammatory arthritic changes were apparent by histopathology and immunohistochemistry (F4/80), immunofluorescence (CD206) and Cy3-tilmanocept binding. In human RA synovial fluid, Cy3-tilmanocept staining correlated with CD206+ /CD16+ cells; negligible labeling was observed in OA samples. Cy3-tilmanocept colocalized with CD206 and staining was significantly higher in RA synovial tissue compared to OA or HV. Our results demonstrate that imaging with Cy3-tilmanocept can detect in vivo inflammatory, CD206+ macrophages in an early arthritis animal model and in human RA patients. These data establish a novel tool for preclinical research of early arthritis and have implications for early RA detection and monitoring of therapeutic efficacy in humans.
Collapse
Affiliation(s)
- Ramiro E Toribio
- Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA
| | - Nicholas Young
- Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Larry S Schlesinger
- Department of Microbial Infection & Immunity, The Ohio State University, Columbus, Ohio, USA.,Texas Biomedical Research Institute, San Antonio, Texas, USA
| | - Fred O Cope
- Navidea Biopharmaceuticals, Inc., Dublin, Ohio, USA.,Physis International LLC, Westerville, Ohio, USA
| | | | - Wael Jarjour
- Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Thomas J Rosol
- Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA
| |
Collapse
|
11
|
Avila C, Jarjour W, Warren P, Kaffenberger BH. Treatment of milk of calcium cysts with sclerotherapy in a dermatomyositis patient. Dermatol Ther 2020; 34:e14689. [PMID: 33340217 DOI: 10.1111/dth.14689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/05/2020] [Accepted: 12/11/2020] [Indexed: 12/01/2022]
Affiliation(s)
- Christina Avila
- The Ohio State University College of Medicine, Columbus, Ohio, USA
| | - Wael Jarjour
- Division of Rheumatology and Immunology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Patrick Warren
- Department of Radiology, Nationwide Children's Hospital, Columbus, Ohio, USA
| | - Benjamin H Kaffenberger
- The Ohio State University College of Medicine, Columbus, Ohio, USA.,Division of Dermatology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| |
Collapse
|
12
|
Hasan LK, Aljabban J, Rohr M, Mukhtar M, Adapa N, Salim R, Aljabban N, Syed S, Syed S, Panahiazar M, Hadley D, Jarjour W. Metaanalysis Reveals Genetic Correlates of Osteoporosis Pathogenesis. J Rheumatol 2020; 48:940-945. [PMID: 33262303 DOI: 10.3899/jrheum.200951] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2020] [Indexed: 01/31/2023]
Abstract
OBJECTIVE Osteoporosis is a growing healthcare burden. By identifying osteoporosis-promoting genetic variations, we can spotlight targets for new pharmacologic therapies that will improve patient outcomes. In this metaanalysis, we analyzed mesenchymal stem cell (MSC) biomarkers in patients with osteoporosis. METHODS We employed our Search Tag Analyze Resource for the Gene Expression Omnibus (STARGEO) platform to conduct a metaanalysis to define osteoporosis pathogenesis. We compared 15 osteoporotic and 14 healthy control MSC samples. We then analyzed the genetic signature in Ingenuity Pathway Analysis. RESULTS The top canonical pathways identified that were statistically significant included the serine peptidase inhibitor kazal type 1 pancreatic cancer pathway, calcium signaling, pancreatic adenocarcinoma signaling, axonal guidance signaling, and glutamate receptor signaling. Upstream regulators involved in this disease process included ESR1, dexamethasone, CTNNβ1, CREB1, and ERBB2. CONCLUSION Although there has been extensive research looking at the genetic basis for inflammatory arthritis, very little literature currently exists that has identified genetic pathways contributing to osteoporosis. Our study has identified several important genes involved in osteoporosis pathogenesis including ESR1, CTNNβ1, CREB1, and ERBB2. ESR1 has been shown to have numerous polymorphisms, which may play a prominent role in osteoporosis. The Wnt pathway, which includes the CTNNβ1 gene identified in our study, plays a prominent role in bone mass regulation. Wnt pathway polymorphisms can increase susceptibility to osteoporosis. Our analysis also suggests a potential mechanism for ERBB2 in osteoporosis through Semaphorin 4D (SEMA4D). Our metaanalysis identifies several genes and pathways that can be targeted to develop new anabolic drugs for osteoporosis treatment.
Collapse
Affiliation(s)
- Laith K Hasan
- L.K. Hasan, BBA, Tulane University School of Medicine, New Orleans, Lousiana;
| | - Jihad Aljabban
- J. Aljabban, MD, MMSc, University of Wisconsin Hospital and Clinics, Madison, Wisconsin
| | - Michael Rohr
- M. Rohr, BS, D. Hadley, MD, PhD, University of Central Florida College of Medicine, Orlando, Florida
| | - Mohamed Mukhtar
- M. Mukhtar, BS, Michigan State University College of Medicine, Lansing, Michigan
| | - Nikhil Adapa
- N. Adapa, MD, State University of New York Upstate Medical University, Syracuse, New York
| | - Rahaf Salim
- R. Salim, BS, Case Western University, Cleveland, Ohio
| | - Nabeal Aljabban
- N. Aljabban, BS, Penn State College of Medicine, Hershey, Pennsylvania
| | - Saad Syed
- S. Syed, BS, S. Syed, MD, Stanford University School of Medicine, Palo Alto, California
| | - Sharjeel Syed
- S. Syed, BS, S. Syed, MD, Stanford University School of Medicine, Palo Alto, California
| | - Maryam Panahiazar
- M. Panahiazar, PhD, University of California San Francisco, San Francisco, California
| | - Dexter Hadley
- M. Rohr, BS, D. Hadley, MD, PhD, University of Central Florida College of Medicine, Orlando, Florida
| | - Wael Jarjour
- W. Jarjour, MD, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| |
Collapse
|
13
|
Xiao ZX, Hu X, Jarjour W, Zheng SG. The role of B7 family members in the generation of Immunoglobulin. J Leukoc Biol 2020; 109:377-382. [PMID: 33118237 DOI: 10.1002/jlb.1mr0420-003rr] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 04/08/2020] [Accepted: 04/15/2020] [Indexed: 10/23/2022] Open
Abstract
Ig is a Y-shaped protein produced by plasma cells and exerts multiple functions in humoral immunity. There are five groups of Igs including IgA, IgD, IgE, IgG, and IgM, which differ in their heavy chain class. The primary function of Igs includes the neutralization of extrinsic pathogens, agglutination of foreign cells for phagocytosis, precipitation of soluble antigens in serum, and complement fixation. The B cells activated by antigen(s) can differentiate into antibody-producing cells that are called plasma cells and usually matured in the germinal center (GC). Follicular T helper (Tfh) cells crosstalk with antigen-presenting cells and play a crucial role in the development of the GC. Moreover, Tfh cells regulate trafficking through the GC to allow formative interaction with GC B cells that ultimately results in affinity maturation, B-cell memory, and Ig class switching. The B7 family is a series of number of structurally related membrane proteins that bind with a specific receptor to deliver costimulatory or co-inhibitory signals that regulate the activation of T cells in GC. Here, we review and summarize the recent advance of the effects of B7 family members on Ig production and relative diseases.
Collapse
Affiliation(s)
- Ze Xiu Xiao
- Institute of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Xiaojiang Hu
- Institute of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Wael Jarjour
- Department of Internal Medicine, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, Ohio, USA
| | - Song Guo Zheng
- Department of Internal Medicine, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, Ohio, USA
| |
Collapse
|
14
|
Aljabban J, Syed S, Syed S, Rohr M, Weisleder N, McElhanon KE, Hasan L, Safeer L, Hoffman K, Aljabban N, Mukhtar M, Adapa N, Allarakhia Z, Panahiazar M, Neuhaus I, Kim S, Hadley D, Jarjour W. Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis. Heliyon 2020; 6:e04866. [PMID: 33015383 PMCID: PMC7522761 DOI: 10.1016/j.heliyon.2020.e04866] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/17/2020] [Accepted: 09/02/2020] [Indexed: 12/17/2022] Open
Abstract
Aims Dermatomyositis (DM) is a progressive, idiopathic inflammatory myopathy with poorly understood pathogenesis. A hallmark of DM is an increased risk for developing breast, ovarian, and lung cancer. Since autoantibodies against anti-TIF-1-γ, a member of the tripartite motif (TRIM) proteins, has a strong association with malignancy, we examined expression of the TRIM gene family to identify pathways that may be contributing to DM pathogenesis. Materials and methods We employed the Search Tag Analyze Resource for GEO platform to search the NCBI Gene Expression Omnibus to elucidate TRIM family gene expression as well as oncogenic drivers in DM pathology. We conducted meta-analysis of the data from human skin (60 DM vs 34 healthy) and muscle (71 DM vs 22 healthy). Key findings We identified genes involved in innate immunity, antigen presentation, metabolism, and other cellular processes as facilitators of DM disease activity and confirmed previous observations regarding the presence of a robust interferon signature. Moreover, analysis of DM muscle samples revealed upregulation of TRIM14, TRIM22, TRIM25, TRIM27, and TRIM38. Likewise, analysis of DM skin samples showed upregulation of TRIM5, TRIM6, TRIM 14, TRIM21, TRIM34, and TRIM38 and downregulation of TRIM73. Additionally, we noted upregulation of oncogenes IGLC1, IFI44, POSTN, MYC, NPM1, and IDO1 and related this change to interferon signaling. While the clinical data associated with genetic data that was analyzed did not contain clinical data regarding malignancy in these cohorts, the observed genetic changes may be associated with homeostatic and signaling changes that relate to the increased risk in malignancy in DM. Significance Our results implicate previously unknown genes as potential drivers of DM pathology and suggest certain TRIM family members may have disease-specific roles with potential diagnostic and therapeutic implications.
Collapse
Affiliation(s)
- Jihad Aljabban
- University of Wisconsin Hospital and Clinics, Madison, WI, USA
| | - Saad Syed
- Stanford University School of Medicine, Palo Alto, CA, USA
| | - Sharjeel Syed
- University of Chicago Medical Center, Chicago, IL, USA
| | - Michael Rohr
- University of Central Florida College of Medicine, Orlando, FL, USA
| | - Noah Weisleder
- The Ohio State University College of Medicine, Columbus, OH, USA
| | | | - Laith Hasan
- Tulane School of Medicine, New Orleans, LA, USA
| | | | - Kalyn Hoffman
- The Ohio State University College of Medicine, Columbus, OH, USA
| | | | - Mohamed Mukhtar
- Michigan State University College of Human Medicine, Lansing, MI, USA
| | | | - Zahir Allarakhia
- The Ohio State University College of Medicine, Columbus, OH, USA
| | | | - Isaac Neuhaus
- University of California San Francisco, San Francisco, CA, USA
| | - Susan Kim
- University of California San Francisco, San Francisco, CA, USA
| | - Dexter Hadley
- University of Central Florida College of Medicine, Orlando, FL, USA
| | - Wael Jarjour
- The Ohio State University College of Medicine, Columbus, OH, USA
| |
Collapse
|
15
|
Dang J, Xu Z, Xu A, Liu Y, Fu Q, Wang J, Huang F, Zheng Y, Qi G, Sun B, Bellanti JA, Kandalam U, Emam HA, Jarjour W, Zheng SG. Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39 -CD73 signaling pathway. J Autoimmun 2020; 113:102491. [PMID: 32565049 DOI: 10.1016/j.jaut.2020.102491] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 04/30/2020] [Accepted: 05/18/2020] [Indexed: 12/21/2022]
Abstract
Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE). Mesenchymal stem cells (MSCs) have emerged as a novel therapy to address the dysregulation in autoimmune diseases but also have limitations. Human gingiva derived MSCs (GMSCs) are superior in regulating immune responses. Here, we demonstrate that the adoptive transfer of GMSCs homes to and maintains in the kidney and has a robust therapeutic effect in a spontaneous lupus nephritis model. Specifically, GMSCs limits the development of autoantibodies as well as proteinuria, decreases the frequency of plasma cells and lupus nephritis histopathological scores by directly suppressing B cells activation, proliferation and differentiation. The blockage of CD39-CD73 pathway dramatically abrogates the suppressive capacities of GMSCs in vitro and in vivo and highlights the significance of this signaling pathway in SLE. Collectively, manipulation of GMSCs provides a promising strategy for the treatment of patients with SLE and other autoimmune diseases.
Collapse
Affiliation(s)
- Junlong Dang
- Department of Clinical Immunology, Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China; Division of Rheumatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, USA
| | - Zhenjian Xu
- Division of Rheumatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, USA; Department of Nephrology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
| | - Anping Xu
- Department of Nephrology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
| | - Yan Liu
- Department of Clinical Immunology, Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China
| | - Qingling Fu
- Otorhinolaryngology Department, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Julie Wang
- Division of Immunology and Rheumatology, Department of Internal Medicine, Ohio State University College of Medicine, USA
| | - Feng Huang
- Department of Clinical Immunology, Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China
| | - Yuejuan Zheng
- Center for Traditional Chinese Medicine and Immunology Research, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
| | - Guangying Qi
- Guangxi State Key Lab, Guilin College of Medicine, Guilin, China
| | - Boqing Sun
- Department of Allergy and Clinical Immunology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Joseph A Bellanti
- Departments of Pediatrics and Microbiology-Immunology, Georgetown University Medical Center, Washington DC, USA
| | - Umadevi Kandalam
- Department of Pediatric Dentistry, College of Dental Medicine, Nova Southeastern University, Davie, FL, USA
| | - Hany A Emam
- Department of Oral & Maxillofacial Surgery, The Ohio State University, Columbus, USA
| | - Wael Jarjour
- Division of Immunology and Rheumatology, Department of Internal Medicine, Ohio State University College of Medicine, USA
| | - Song Guo Zheng
- Division of Immunology and Rheumatology, Department of Internal Medicine, Ohio State University College of Medicine, USA.
| |
Collapse
|
16
|
Meara A, Lamoreaux B, Steigleman H, Yedimenko J, Jarjour W, Rovin B, Parikh S, Ayoub I, Ardoin SP. Frequency of Cytomegalovirus Seropositivity and Viremia in a Midwestern University Lupus Population. J Clin Rheumatol 2020; 26:157-159. [PMID: 32453289 DOI: 10.1097/rhu.0000000000001390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Alexa Meara
- From the Department of Internal Medicine, and Division of Rheumatology and Immunology, Ohio State University Wexner Medical Center, Columbus, OH
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Zheng SG, Chen Y, Jarjour W, Wang J. CD126 negative regulatory cells represents a superior Treg subset in treating autoimmune diseases. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.237.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Abstract
Treg cells play an important role in maintaining immunologic homeostasis. Abnormal Treg were found in some autoimmune diseases. Infusion of natural Treg (nTreg) prevents some autoimmune disease but usually fails to treat established diseases. Several studies demonstrated nTreg could be transdifferentiated into Th17 cells and lost its function under inflammatory condition. Given IL-6 is an important inflammatory cytokine and it binds to its receptor (CD126) to exert functional role, whereas nTreg express CD126, we hypothesize that CD126− Foxp3+ cell subsets could be more stable and functional in the inflammatory condition.
CD126+ and CD126− nTreg were sorted from collagen-induced arthritis (CIA) and then were analyzed for transcript difference via RNA-sequence. They were cultured in the presence of IL-6 to determine the stability and function following a colitis model in vivo.
Compared to normal mice, the proportion of CD126+ nTreg in CIA was significantly higher. CD126− nTreg express higher immunosuppressive molecules and present stronger function than CD126+ nTreg in both normal condition and presence of IL-6. Moreover, CD126− nTreg was stable while CD126+ nTreg lost Foxp3 expression and trans-differentiated into Th17 in the presence of IL-6. In addition, CD126− nTreg exhibited reduced Hif-1a and glucose transporter 1(Slc2a1) expression, which are two key regulators of glycolytic metabolism and play an important role in the balance of Th17 and Treg. Finally, CD126− Treg more potent treat colitis compared to control.
We show CD126− nTreg present stronger function and stability under inflammatory conditions Our results suggest that manipulation of CD126− nTreg might be a novel strategy for the treatment of autoimmune diseases.
Collapse
Affiliation(s)
| | - Ye Chen
- 1The Ohio State University, College of Medicine
| | | | - Julie Wang
- 1The Ohio State University, College of Medicine
| |
Collapse
|
18
|
Zheng SG, Zhang X, Jarjour W, Wang J. Human gingiva-derived mesenchymal stem cells ameliorate rheumatoid arthritis through directly targeting of rheumatoid arthritis synovial fibroblasts. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.219.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Rheumatoid arthritis (RA) is a systemic-autoimmune-mediated disease characterized by synovial hyperplasia and progressive destruction of joint. The aim of this study is to evaluate whether human gingiva derived MSCs (GMSCs) can alleviate rheumatoid arthritis through directly targeting of rheumatoid arthritis synovial fibroblasts (RA-SF) and underlying mechanism(s).
GMSCs or Primary Dermal Fibroblast (PDF) were co-cultured with LPS-stimulated RA-SF. The proliferation, migration and invasion abilities of RA-SF or GMSCs treated RA-SF were examined for determining the suppressive effects of GMSCs on RA-SF. To learn whether GMSCs suppress RA-SF migration and invasion in vivo, GMSCs were subcutaneously co-transplanted with RA-SF and health cartilage into SCID mice to develop a humanized synovitis model, H&E or immunofluorescence staining were employed to determine the effects. Moreover, GMSCs were transferred into collagen induced arthritis model (CIA), proliferation, migration and invasion capacities of synovial fibroblasts from model mice or GMSCs treated mice were compared.
We found that the proliferation, migration and invasion capacities of GMSCs treated RA SF were significantly declined. Importantly, the expression of IL-6, IL-8, MMP1, MMP2, MMP3 and MMP13 were dramatically reduced in GMSCs treated RA-SF (qPCR results). Administration of GMSCs was therapeutic in collagen induced arthritis synovial fibroblasts pathology (proliferation, migration and invasion). Furthermore, GMSCs directly suppress RA-SF invasion in a humanized synovitis model.
We conclude that the manipulation of GMSCs can ameliorate rheumatoid arthritis (RA) through directly targeting of rheumatoid arthritis synovial fibroblasts.
Collapse
Affiliation(s)
| | - Ximei Zhang
- 1The Ohio State University, College of Medicine
| | | | - Julie Wang
- 1The Ohio State University, College of Medicine
| |
Collapse
|
19
|
Liu Y, Jarjour W, Olsen N, Zheng SG. Traitor or warrior-Treg cells sneaking into the lesions of psoriatic arthritis. Clin Immunol 2020; 215:108425. [PMID: 32305454 DOI: 10.1016/j.clim.2020.108425] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 04/14/2020] [Accepted: 04/14/2020] [Indexed: 01/01/2023]
Abstract
Regulatory T (Treg) cells have been recognized to maintain immune tolerance, which contributes to prevention of autoimmune diseases. However, recent evidence has demonstrated different characteristics of these cells between those that are in circulation compared to those in various local tissues. In addition, the ability of Treg cells to have plasticity in certain disease settings and in inflammatory lesions has been increasingly recognized. Herein we summarize updated knowledge of Treg biology and discuss the current understanding of tissue-resident Treg cells in psoriatic arthritis (PsA), attempting to provide new insights into precise role of Treg cells in the immune response and as a possible therapeutic intervention in patients with PsA.
Collapse
Affiliation(s)
- Yan Liu
- Institute of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510620, China
| | - Wael Jarjour
- Department of Internal Medicine, The Ohio State University College of Medicine, Wexner Medical Center, Columbus 43210, USA
| | - Nancy Olsen
- Department of Medicine, The Penn State Hershey College of Medicine, Hershey 17031, USA
| | - Song Guo Zheng
- Department of Internal Medicine, The Ohio State University College of Medicine, Wexner Medical Center, Columbus 43210, USA.
| |
Collapse
|
20
|
Willis W, Foster A, Henry C, Wu LC, Jarjour W. In vitro Crosslinking Reactions and Substrate Incorporation Assays for The Identification of Transglutaminase-2 Protein Substrates. Bio Protoc 2020; 10:e3657. [DOI: 10.21769/bioprotoc.3657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Revised: 04/17/2020] [Accepted: 04/21/2020] [Indexed: 11/02/2022] Open
|
21
|
Das M, Deb M, Laha D, Joseph M, Kanji S, Aggarwal R, Iwenofu OH, Pompili VJ, Jarjour W, Das H. Myeloid Krüppel-Like Factor 2 Critically Regulates K/BxN Serum-Induced Arthritis. Cells 2019; 8:cells8080908. [PMID: 31426355 PMCID: PMC6721677 DOI: 10.3390/cells8080908] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 07/29/2019] [Accepted: 08/15/2019] [Indexed: 01/14/2023] Open
Abstract
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, and Krüppel-like factor 2 (KLF2) regulates immune cell activation and function. Herein, we show that in our experiments 50% global deficiency of KLF2 significantly elevated arthritic inflammation and pathogenesis, osteoclastic differentiation, matrix metalloproteinases (MMPs), and inflammatory cytokines in K/BxN serum-induced mice. The severities of RA pathogenesis, as well as the causative and resultant cellular and molecular factors, were further confirmed in monocyte-specific KLF2 deficient mice. In addition, induction of RA resulted in a decreased level of KLF2 in monocytes isolated from both mice and humans along with higher migration of activated monocytes to the RA sites in humans. Mechanistically, overexpression of KLF2 decreased the level of MMP9; conversely, knockdown of KLF2 increased MMP9 in monocytes along with enrichment of active histone marks and histone acetyltransferases on the MMP9 promoter region. These findings define the critical regulatory role of myeloid KLF2 in RA pathogenesis.
Collapse
Affiliation(s)
- Manjusri Das
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - Moonmoon Deb
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Dipranjan Laha
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Matthew Joseph
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - Suman Kanji
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Reeva Aggarwal
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - O Hans Iwenofu
- Department of Pathology, College of Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - Vincent J Pompili
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - Wael Jarjour
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA
| | - Hiranmoy Das
- Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
| |
Collapse
|
22
|
Guerau-De-Arellano M, Amici SA, Young N, Papenfuss TL, Torrelles J, Jarjour W. CD38: biomarker and functional role in human macrophages. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.49.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Macrophages mediate innate immune responses via a spectrum of phenotypes that range from inflammatory to resolving. We previously identified CD38 as a robust marker of inflammatory macrophages useful in both murine in vitro and in vivo models. We hypothesized that CD38 plays a similar biomarker and/or functional role in human macrophages and autoimmune inflammatory disease. Using human macrophages of primary or monocytic cell line origin, we found that CD38 is robustly induced in human macrophages exposed to LPS and IFN-g inflammatory stimuli, but not with the alternative stimulus, IL-4. Analyses in the systemic autoimmune disease Systemic Lupus Erythematosus (SLE) revealed that CD38hi classical and non-classical monocyte subpopulations are associated with disease activity. In addition, genetic or pharmacologic CD38 loss-of-function in human primary macrophages resulted in suppressed inflammatory cytokines IL-6 and IL-12p40 secretion in human primary macrophages. Taken together, these findings support a biomarker and functional role for CD38 in inflammatory macrophages/monocytes and inflammatory disease.
Collapse
|
23
|
Abstract
Introduction Systemic lupus erythematosus (SLE) is a complex disease that is associated with significant mortality and an increased risk of hospitalization. Several validated instruments are available to measure disease activity in SLE patients. However, these instruments were not designed to screen for SLE patients at an increased risk of hospitalization. These instruments also fail to incorporate some data that are easily obtainable from electronic health records, such as the frequency of missed outpatient appointments. Methods All patients at a single academic medical center with an International Classification of Disease (ICD-10) code for SLE (M32) that were seen at least once between 2010 and 2017 were identified. Of these 3552 patients, 813 were randomly selected for chart review using a random number generator, and 226 were verified to have seen an outpatient rheumatologist and met the American College of Rheumatology Classification Criteria for SLE. Physician notes, laboratory values, and appointment information were reviewed, and relevant data were extracted. Weighted Cox regression models were used to estimate the risk of hospitalization and develop a screening algorithm, and receiver operating characteristic (ROC) curve analysis was performed to evaluate the algorithm. Results There were 160 patients with no lupus-related hospitalizations and 66 patients with such a hospitalization. In a multivariate analysis accounting for age, gender, and race, serum creatinine >1.20 mg/dL, white blood cell count > 10 (thousand)/µL, hemoglobin <11 g/dL, platelets < 180 (thousand)/µL, high risk immunosuppression use, missing between 0 and 20% of appointments, and missing ≥ 20% of appointments were associated with an increased risk of hospitalizations. Our proposed screening algorithm does well identifying SLE patients at risk of hospitalization (area under the curve (AUC): 0.90, 95% CI: 0.86-0.94). We recommend flagging patients with a score of ≥ 3 (sensitivity: 0.95; specificity: 0.54). Conclusions A new screening algorithm accounting for serum creatinine, white blood cell count, hemoglobin, platelets, high-risk immunosuppression, and the proportion of missed appointments may be useful in identifying SLE patients at an increased risk of hospitalization. Missing appointments may be a proxy for an underlying variable (such as access to health care) that is directly related to an increased risk of hospitalization.
Collapse
Affiliation(s)
- D Li
- 1 The Ohio State University College of Medicine, Columbus, USA
| | - H M Madhoun
- 2 Department of Internal Medicine, Division of Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, USA
| | - W N Roberts
- 3 Department of Internal Medicine, Division of Rheumatology, University of Louisville, Louisville, USA
| | - W Jarjour
- 2 Department of Internal Medicine, Division of Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, USA
| |
Collapse
|
24
|
Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M. Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225]. Nucl Med Biol 2016; 43:837. [PMID: 27866590 DOI: 10.1016/j.nucmedbio.2016.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Frederick O Cope
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
| | - Bonnie Abbruzzese
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - James Sanders
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Wendy Metz
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kristyn Sturms
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - David Ralph
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Michael Blue
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Jane Zhang
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110
| | - Paige Bracci
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110
| | - Wiam Bshara
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Spencer Behr
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Toby Maurer
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Kenneth Williams
- Boston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, MA 02467
| | - Joshua Walker
- Boston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, MA 02467
| | - Allison Beverly
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Brooke Blay
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Anirudh Damughatla
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Mark Larsen
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Courtney Mountain
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Erin Neylon
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kaeli Parcel
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kapil Raghuraman
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kevin Ricks
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Lucas Rose
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Akhilesh Sivakumar
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Nicholas Streck
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Bryan Wang
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Christopher Wasco
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Amifred Williams
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Larry S Schlesinger
- Center for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210
| | - Abul Azad
- Center for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210
| | - Murugesan V S Rajaram
- Center for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210
| | - Wael Jarjour
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University, Columbus, OH 43210
| | - Nicholas Young
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University, Columbus, OH 43210
| | - Thomas Rosol
- The School of Veterinary Medicine, The Ohio State University, Columbus, OH 43210
| | - Michael McGrath
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110
| |
Collapse
|
25
|
Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos RT, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang SM. Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients. J Clin Endocrinol Metab 2016; 101:4085-4093. [PMID: 27533304 PMCID: PMC5095242 DOI: 10.1210/jc.2016-1605] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Sialadenitis and xerostomia are major adverse effects of 131I therapy in thyroid cancer patients. The risk factors for these adverse effects, other than administered activity of 131I, have not been investigated. OBJECTIVE The aim of this study is to identify risk factors for 131I-induced salivary gland damage among follicular cell-derived thyroid cancer patients. DESIGN We enrolled 216 thyroid cancer patients who visited The Ohio State University Wexner Medical Center between April 2013 and April 2014. Symptoms of xerostomia and sialadenitis were identified via questionnaire and medical record search. To validate the findings in a large cohort, we retrospectively searched for ICD-9/10 codes for sialadenitis, xerostomia, and autoimmune disease associated with Sjögren's syndrome (AID-SS) in our existing database (n = 1507). Demographic and clinical information was extracted from medical records. Multivariate analyses were performed to identify independent predictors for salivary gland damage. RESULTS 131I treatment associated with higher incidence of xerostomia and sialadenitis. Patients with xerostomia had 46 mCi higher mean cumulative 131I activity and 21 mCi higher mean first-administered 131I activity than patients without xerostomia. Increased age associated with higher incidence of xerostomia, and females had a higher incidence of sialadenitis. Patients who experienced sialadenitis before 131I therapy had higher sialadenitis incidence after 131I therapy. 131I-treated patients diagnosed with AID-SS, whether before or after 131I treatment, had a higher incidence of xerostomia and sialadenitis among 131I-treated patients. CONCLUSION Risk factors for 131I-induced salivary gland damage include administered 131I activity, age, gender, history of sialadenitis before 131I treatment, and AID-SS diagnosis.
Collapse
Affiliation(s)
- Brynn Hollingsworth
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Leigha Senter
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Xiaoli Zhang
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Guy N Brock
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Wael Jarjour
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Rebecca Nagy
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Pamela Brock
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Kevin R Coombes
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Richard T Kloos
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Matthew D Ringel
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Jennifer Sipos
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Ilene Lattimer
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Ricardo Carrau
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| | - Sissy M Jhiang
- Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210
| |
Collapse
|
26
|
Young N, Hampton J, Kalyanasundaram A, Bratasz A, Pyles J, Aqel S, Jarjour W, Ardoin S. OP0161 Cardiac Magnetic Resonance Imaging of Lupus Nephritis-Induced Cardiovascular Disease Correlates with Myocarditis, Fibrosis, and Enhanced Pro-Inflammatory Cytokine Expression in A Mouse Model. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Young N, Valiente G, Hampton J, Steigelman H, Jarjour W. SAT0027 Inhibition of Tlr7 and Tlr8 Signaling by Antagonizing Micro-Rna Derived from Extracellular Vesicles Suppresses Inflammation in A Novel Human-Mouse Chimeric Model of Lupus. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Aqel S, Hampton J, Valiente G, Sheridan J, Jarjour W, Young N. FRI0027 The Inflammatory Pathology of Lupus Nephritis Is Significantly Induced with Psychosocial Stress, Suppressed with Exercise, and Correlates with TNF-Alpha and MCP-1 Expression in A Murine Model. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Kaffenberger BH, Kaffenberger JA, Wong H, Jarjour W, Levin D, Bechtel MA. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate? Int J Dermatol 2016; 54:752-6. [PMID: 26108262 DOI: 10.1111/ijd.12923] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The liver biopsy has been regarded as the reference standard method of monitoring hepatic fibrosis in psoriasis patients treated with methotrexate. It has also been subject to concerns over sampling error, internal and external variability, and potential for morbidity and mortality. During the past two decades, two imaging techniques, magnetic resonance elastography and transient elastography, have been developed and approved by the US Food and Drug Administration (FDA) for the assessment of hepatic fibrosis. Although high-quality, psoriasis-specific data are lacking, both methods have been shown to have outstanding efficacy in the detection of hepatic fibrosis, particularly the more advanced stages which may warrant the choice of a therapeutic alternative to methotrexate. Dermatologists should be aware of the availability of these tests and understand their limitations. Prospective studies in psoriasis and methotrexate management using these techniques are needed.
Collapse
Affiliation(s)
| | - Jessica A Kaffenberger
- Department of Dermatology, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Henry Wong
- Department of Dermatology, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Wael Jarjour
- Department of Rheumatology, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Douglas Levin
- Department of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Mark A Bechtel
- Department of Dermatology, Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|
30
|
Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, Williams A, McGrath M. The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. Nucl Med Biol 2016; 43:215-25. [PMID: 26924502 PMCID: PMC4794336 DOI: 10.1016/j.nucmedbio.2015.11.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 11/13/2015] [Accepted: 11/16/2015] [Indexed: 12/30/2022]
Abstract
In considering the challenges of approaches to clinical imaging, we are faced with choices that sometimes are impacted by rather dogmatic notions about what is a better or worse technology to achieve the most useful diagnostic image for the patient. For example, is PET or SPECT most useful in imaging any particular disease dissemination? The dictatorial approach would be to choose PET, all other matters being equal. But is such a totalitarian attitude toward imaging selection still valid? In the face of new receptor targeted SPECT agents one must consider the remarkable specificity and sensitivity of these agents. (99m)Tc-Tilmanocept is one of the newest of these agents, now approved for guiding sentinel node biopsy (SLNB) in several solid tumors. Tilmanocept has a Kd of 3×10(-11)M, and it specificity for the CD206 receptor is unlike any other agent to date. This coupled with a number of facts, that specific disease-associated macrophages express this receptor (100 to 150 thousand receptors), that the receptor has multiple binding sites for tilmanocept (>2 sites per receptor) and that these receptors are recycled every 15 min to bind more tilmanocept (acting as intracellular "drug compilers" of tilmanocept into non-degraded vesicles), gives serious pause as to how we select our approaches to diagnostic imaging. Clinically, the size of SLNs varies greatly, some, anatomically, below the machine resolution of SPECT. Yet, with tilmanocept targeting, the SLNs are highly visible with macrophages stably accruing adequate (99m)Tc-tilmanocept counting statistics, as high target-to-background ratios can compensate for spatial resolution blurring. Importantly, it may be targeted imaging agents per se, again such as tilmanocept, which may significantly shrink any perceived chasm between the imaging technologies and anchor the diagnostic considerations in the targeting and specificity of the agent rather than any lingering dogma about the hardware as the basis for imaging approaches. Beyond the elements of imaging applications of these agents is their evolution to therapeutic agents as well, and even in the neo-logical realm of theranostics. Characteristics of agents such as tilmanocept that exploit the natural history of diseases with remarkably high specificity are the expectations for the future of patient- and disease-centered diagnosis and therapy.
Collapse
Affiliation(s)
- Frederick O Cope
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
| | - Bonnie Abbruzzese
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - James Sanders
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Wendy Metz
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kristyn Sturms
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - David Ralph
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Michael Blue
- Navidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017
| | - Jane Zhang
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207 San Francisco, CA 94110
| | - Paige Bracci
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207 San Francisco, CA 94110
| | - Wiam Bshara
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Spencer Behr
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Toby Maurer
- Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263
| | - Kenneth Williams
- Boston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, Massachusetts 02467
| | - Joshua Walker
- Boston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, Massachusetts 02467
| | - Allison Beverly
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Brooke Blay
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Anirudh Damughatla
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Mark Larsen
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Courtney Mountain
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Erin Neylon
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kaeli Parcel
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kapil Raghuraman
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Kevin Ricks
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Lucas Rose
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Akhilesh Sivakumar
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Nicholas Streck
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Bryan Wang
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Christopher Wasco
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | | | | | | | | | | | | | - Amifred Williams
- Navidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017
| | - Michael McGrath
- The University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207 San Francisco, CA 94110
| |
Collapse
|
31
|
Young N, Wu LC, Amici S, Guerau M, Severin M, Lovett-Racke A, Valiente G, Burd C, Hampton J, Jarjour W. AB0050 Estrogen-Regulated STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing MIR-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Young N, Wu LC, Gardner M, Hampton J, Bruss M, Jarjour W. AB0185 Nano-Emulsified Curcumin (NEC), a Patented Anti-Inflammatory Nutraceutical Compound Developed At Ohio State, Reduces Renal Pathology in an Animal Model of Lupus Nephritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Young N, Agarwal S, Aqel S, Hampton J, Jones K, Wu LC, Powell N, Sheridan J, Bruss M, Jarjour W. THU0378 Moderate Exercise is Beneficial and Social Stress is Detrimental to Disease Progression in an Animal Model of Lupus Nephritis: Extra-Medicinal Influences in Autoimmune Disease. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Blazek A, Knapik D, Young N, Wu LC, Jarjour W, Agarwal S. OP0109 Exercise Suppresses Systemic Inflammation via Inhibition of Nf-Kb Activation in Monocytes. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Young N, Wu LC, Burd C, Bruss M, Valiente G, Jarjour W. AB0187 Estrogen-Induction of STAT1 and STAT4 Expression by Estrogen Receptor Alpha Suggests a Novel IFN-Alpha-Independent Mechanism of Sex-Bias in Systemic Lupus Erythematosus Pathogenesis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Agarwal S, Blazek AD, Wu LC, Young N, Eubank T, Hewett T, Jarjour W, Weisleder N. Exercise Suppresses Local And Systemic Inflammation Via Nf-kb Inhibition. Med Sci Sports Exerc 2014. [DOI: 10.1249/01.mss.0000493705.09674.d4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
37
|
Kaffenberger BH, Lee GL, Tyler K, Chan DV, Jarjour W, Ariza ME, Williams MV, Wong HK. Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother 2014; 10:876-86. [PMID: 24492530 DOI: 10.4161/hv.27532] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Psoriasis is a chronic, immune skin disease associated with significant morbidity. Development of psoriasis is influenced by numerous genes, one allele is HLA-CW*0602. Other genes and single nucleotide polymorphisms affect immunologic pathways and antimicrobial peptide synthesis. Dendritic cells initiate psoriasis by activating T-cells toward a Th1 and Th17 response, with increased cytokines including TNF-α, IL-6, -12, -17, -22, and -23. IL-22 appears to promote keratinocyte dedifferentiation and increased antimicrobial peptide synthesis while TNF-α and IL-17 induce leukocyte localization within the psoriatic plaque. These recent insights identifying key cytokine pathways have led to the development of inhibitors with significant efficacy in the treatment of psoriasis. While a strategy for vaccine modulation of the immune response in psoriasis is in progress, with new technology they may provide a cost-effective long-term treatment that may induce tolerance or targeted self-inhibition for patients with autoimmune disorders, such as psoriasis.
Collapse
Affiliation(s)
- Benjamin H Kaffenberger
- Division of Dermatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Grace L Lee
- Division of Dermatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Kelly Tyler
- Division of Dermatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Derek V Chan
- Division of Dermatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Wael Jarjour
- Division of Rheumatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Maria E Ariza
- Department of Medical Virology, Immunology, and Molecular Genetics; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Marshall V Williams
- Department of Medical Virology, Immunology, and Molecular Genetics; Ohio State University Wexner Medical Center; Columbus, OH USA
| | - Henry K Wong
- Division of Dermatology; Department of Internal Medicine; Ohio State University Wexner Medical Center; Columbus, OH USA
| |
Collapse
|
38
|
Young N, Friedman A, Kaffenberger B, James H, Wu LC, Shupnik M, Jarjour W. AB0221 Estrogen modulation of endosome-associated toll-like receptors and ZAS3: An underlying mechanism of gender-BIAS in systemic lupus erythematosus? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. J Am Acad Dermatol 2012; 68:489-92. [PMID: 22981608 DOI: 10.1016/j.jaad.2012.08.021] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2012] [Revised: 08/03/2012] [Accepted: 08/14/2012] [Indexed: 11/19/2022]
Abstract
Hematopoietic stem-cell transplantation (HSCT) has emerged as an effective immunotherapy for several severe autoimmune diseases. A comprehensive search of the existing literature was performed for patients with psoriasis and HSCT. Nineteen patients have been reported to have psoriasis resolution after allogeneic or autologous HSCT. In the allogeneic setting, 10 of 13 were noted to have durable remission of their psoriasis with a mean follow-up of 49 months. Two cases that did reoccur were only transient. Six patients underwent autologous transplantation. Of these, 5 of 6 developed a recurrence of their psoriasis within 2 years. Based on a limited number of patients, psoriasis is likely to remit after allogeneic HSCT, but it is likely to recur after autologous HSCT.
Collapse
|
40
|
Jarjour W, Reed AM, Gauthier J, Hunt S, Winfield JB. The 8.5-kb PstI allele of the stress protein gene, Hsp70-2: an independent risk factor for systemic lupus erythematosus in African Americans? Hum Immunol 1996; 45:59-63. [PMID: 8655362 DOI: 10.1016/0198-8859(95)00153-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
SLE is dramatically more prevalent in persons of African descent than in other populations. Several genes in the class III region of the MHC have been considered as potential susceptibility loci for this disorder, but the primary association(s) remains unknown. The stress protein gene, hsp70-2, is of special interest in this regard because it encodes a protein functionally relevant to antigen processing and presentation and has itself been identified as a putative susceptibility locus in organ-specific autoimmune diseases in Caucasians. To clarify the relationship of the hsp70-2 gene to SLE in African Americans, genomic DNA from 46 patients and 42 appropriately matched control subjects was analyzed for an RFLP of the hsp70-2 gene using the probe pH2.3 and the restriction endonuclease PstI, which identifies alleles of 8.5 and 9.0 kb. The 8.5-kb hsp70-2 allele was associated with SLE in this population (X2 = 8.2473, p = 0.0044). This association was not due to linkage disequilibrium with the C4A deletion or with HLA-DR3, as has been reported in Caucasians with IDDM. These data suggest that the 8.5-kb hsp70-2 allele may be an independent susceptibility marker for SLE in African Americans.
Collapse
Affiliation(s)
- W Jarjour
- Thurston Arthritis Research Center, University of North Carolina at Chapel Hill 27599, USA
| | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- J Winfield
- Thurston Arthritis Research Center, University of North Carolina at Chapel Hill 27599
| | | |
Collapse
|
42
|
Affiliation(s)
- J Winfield
- Division of Rheumatology and Immunology, University of North Carolina, Chapel Hill 27599
| | | |
Collapse
|
43
|
Jarjour W, Mizzen LA, Welch WJ, Denning S, Shaw M, Mimura T, Haynes BF, Winfield JB. Constitutive expression of a groEL-related protein on the surface of human gamma/delta cells. J Exp Med 1990; 172:1857-60. [PMID: 1979591 PMCID: PMC2188754 DOI: 10.1084/jem.172.6.1857] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Rabbit antibodies to hsp58 (P1), the human homologue of the Escherichia coli stress protein groEL, react specifically in indirect immunofluorescence and complement-dependent microcytoxicity experiments with a cell surface antigen expressed constitutively by T cell lines bearing gamma/delta receptors. This anti-hsp58-reactive antigen is not demonstrable on T cells that express alpha/beta receptors or on various cells that lack T cell receptors. Certain evidence was obtained to suggest that the target antigen on the surface of gamma/delta T cells is a approximately 77-kD protein distinct from intracellular hsp58 and known members of the hsp70 stress protein family. While the exact nature and significance of this anti-hsp58-reactive protein remain to be determined, these data may help to clarify the roles of groEL-related stress proteins and gamma/delta cells that recognize groEL homologous in immunologic defense against infection and in autoimmune disease.
Collapse
Affiliation(s)
- W Jarjour
- Division of Rheumatology and Immunology, University of North Carolina, Chapel Hill 27514
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Nearly one-third of IgM antilymphocyte autoantibody-positive sera from patients with systemic lupus erythematosus (SLE) contain IgM antibodies to one or more 180-220-kD molecules (p180, p190, p205, and p220) in blots of glycoproteins purified from T cells by wheat germ agglutinin affinity chromatography. Identity of these IgM targets with multiple isoforms of CD45 was established by their specific depletion from T cell glycoproteins by immunoprecipitation with T191, a monoclonal antibody (mAb) that reacts with an epitope common to all CD45 isoforms. Although the anti-CD45 autoantibodies recognize higher molecular weight isoforms primarily, antigenic specificity in this system is quite heterogeneous and includes multiple distinct CD45 isoforms on different types of T cells that are, at least in part, different from those reactive with mAbs 2H4 and UCHL-1. Because CD45 is a major membrane protein tyrosine phosphatase that plays a critical role in antigen-induced T cell activation, the present data may be relevant to some of the antilymphocyte antibody-mediated immunologic abnormalities that characterize SLE and related autoimmune diseases.
Collapse
Affiliation(s)
- T Mimura
- Division of Rheumatology and Immunology, University of North Carolina, Chapel Hill 27514
| | | | | | | |
Collapse
|
45
|
Mimura T, Fernsten P, Shaw M, Jarjour W, Winfield JB. Glycoprotein specificity of cold-reactive IgM antilymphocyte autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1990; 33:1226-32. [PMID: 2202314 DOI: 10.1002/art.1780330824] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Sera from patients with systemic lupus erythematosus frequently contain IgM antibodies to glycoproteins of Mr 46,000 and approximately 200,000 isolated from nonionic detergent lysates of mature T cells by affinity chromatography with solid-phase wheat germ agglutinin. Autoantibodies of this specificity correlate strongly with the presence of IgM anti-T cell autoantibodies, as determined by independent indirect immunofluorescence and complement-dependent microcytotoxicity assays, and are specifically absorbed by incubation of patient serum with viable T cells. Collectively, the data suggest that gp46 and, to a lesser extent, gp approximately 200 represent major targets of IgM antilymphocyte autoantibodies in systemic lupus erythematosus.
Collapse
Affiliation(s)
- T Mimura
- Division of Rheumatology and Immunology, Thurston Arthritis Research Center, University of North Carolina, Chapel Hill
| | | | | | | | | |
Collapse
|